Landmark GLP-1 receptor agonist trials — including those establishing semaglutide and tirzepatide as transformative obesity treatments — routinely fail to measure and report comprehensive dietary intake data, despite appetite suppression and reduced energy consumption being the primary mechanisms driving weight loss. This perspective from Emory's Department of Human Genetics invokes all four classical bioethical principles — autonomy, non-maleficence, beneficence, and justice — to argue that this omission is not merely a methodological oversight but an ethical failure. Specific harms identified include lean mass loss and micronutrient deficiencies from inadequately characterized energy and protein restriction.
This critique lands at a clinically urgent moment. With GLP-1RA prescriptions scaling into the tens of millions globally, practitioners are making long-term treatment decisions with virtually no trial-level data on what patients are actually eating or how nutritional adequacy shifts over months of pharmacotherapy. The lean mass erosion concern is particularly serious — existing data suggest 25–40% of GLP-1RA-driven weight loss may be fat-free mass, a ratio with profound implications for metabolic health, frailty, and aging trajectories. While this is a perspective piece rather than original empirical research — and therefore generates no new data — its framework for requiring preregistered dietary endpoints, CONSORT-aligned nutrition reporting, and embedded registered dietitians is actionable and overdue. Incremental in argument but potentially paradigm-shifting in consequence if adopted by regulators and journal editors.
